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Carbon Disulfide
Neurotoxicity Defined
In 1997, a team ofresearchers based at the
NIEHS was awarded a Bronze Medal for
Commendable Service by the EPA for a
series of studies on the neurotoxicity of
carbon disulfide (CS2). Performed in col-
laboration with scientists from the EPA,
Duke University Medical Center in
Durham, North Carolina, and the
University of North Carolina at Chapel
Hill, the studies are unique in their com-
prehensive examination of the sensitive
biochemical, functional, and structural
changes to the nervous system resulting
from exposure to CS2. The findings have
providedvaluable insight into the processes
underlying CS2 neurotoxicity, and offer a
model for the study of effects of exposure
to other toxic compounds.
CS2 has been used since the early nine-
teenth century as a solvent in the manufac-
ture ofsulfur matches and in the extraction
of fats. It has also been used in the cold
vulcanization of rubber; clinical signs of
nerve damage associated with both acute
and chronic exposures were first described
in rubber industry workers. Cold vulcan-
ization was eventually replaced by other
processes that do not use CS2, but the
compound is still used today in the pro-
duction of rayon and cellophane from
wood fiber (because CS2 serves as a reac-
tant in this process, replacement with a
nontoxic chemical has not been possible).
The U.S. Department of Health and
Human Services estimates total atmospher-
ic discharges of CS2 to be approximately
76 million pounds peryear.
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and increased the confidence in the results.
"It was very critical to the success ofthe
project to be able to conduct all the studies
13 at one place using the same animals," Sills
says. "That way, we knew the animals were
exposed to the exact same dosages and kept
under the same experimental conditions.
The same scientific staff and equipment
were employed throughout the study, all of
which cuts way down on the variables.
Inhalation studies are very expensive, cost-
ing $150,000-200,000 by some estimates.
Because we were able to use the same ani-
mals for each of the six studies, we were
able to save a tremendous amount of
money.
The studies were designed to assess mul-
tiple biological and mechanistic endpoints
at various time periods ofsubchronic expo-
sure. Researchers used Fischer 344 rats, a
strain used in previous CS2 inhalation stud-
dto800 ppmCS2. ies. Rats were exposed to either 0, 50, 500,
162(1998M. or 800 parts per million (ppm) CS2 for 6
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hours per day, 5 days per week, for 2, 4, 8,
or 13 weeks.
An important consideration in design-
ing the studies was the need to correlate the
inhaled CS2 dose and the neurobehavioral,
neurophysiological, and neuropathological
effects. To do this, it was essential that all
the endpoints be obtained on all ofthe ani-
mals. These endpoints included pharmaco-
kinetic changes in blood CS2 levels and uri-
narymetabolites, blood and spinal cord bio-
markers ofexposure and effect, neurotoxici-
ty alterations in axon-Schwann cell interac-
tions, pathology ofthe peripheral nerve and
spinal cord, nerve conduction velocity
(NCV), compound nerve action potential
(CNAP), and behavioral assessments usinga
Functional Observational Battery (FOB).
Immediately following exposure on the day
priorto thepenultimate exposure, urinewas
collected for metabolic analysis. During and
after the next inhalation exposure, blood
was collected for analysis of CS2 and
metabolites. Following the last exposure,
rats were examined by FOB and then
assessed for electrophysiological function.
Next, 5 rats per sex per dose group were
evaluated for the presence of CS2
protein-protein cross-linking in the red
blood cells and the neurofilaments of the
spinal cord. Segments of the sciatic nerve
were collected and analyzed for alterations
in the low-affinity nerve growth factor
receptor (NGF-R) mRNA. Four rats per
sex per dose group were selected for the
morphologicevaluations.
Results
One ofthe prerequisites for characterizing
the toxicity ofany compound is to under-
stand how the compound is taken up by
the body and either retained or eliminated.
The concentration and duration of expo-
sure and the number of previous days of
exposure to the compound all can affect
the amount that is actually retained. To
evaluate the relationship between measures
of the inhalation exposure to CS2 and the
toxicologic response and biomarkers of
exposure, the research team performed
three separate studies characterizing CS2
kinetics in the test animals.
A single exposure inhalation study was
conducted to investigate the uptake and
elimination kinetics ofCS2. Asingle-expo-
sure intravenous study was also conducted
to estimate the volume ofdistribution and
total systemic dearance. Finally, a 13-week
inhalation study involving repeated expo-
sures characterized the plateau of CS2
blood levels and 2-thiothiazolidine-4-car-
boxylicacid(TTCA) excretion.
The studies found that, at the concen-
trations tested (50, 500, and 800 ppm),
I
Theresults are in.The award-winning CS2 stud-
ies were published in a special section in the
February 1998 issue ofNeurotoxicology.
there is not alinear dose-response relation-
ship between the amount of CS2 inhaled
and either blood CS2 concentration or uri-
nary TTCA excretion. Both blood CS2
and urinary TTCA became saturated at
these higher levels. Thus, these measures
appear to be useful only as indicators of
exposure to relatively low levels of CS2
exposure andshort exposure time frames.
Using samples obtained from the
NIEHS collaboration, it was demonstrated
that covalent cross-linking of neurofila-
ment proteins was a direct effect of CS2
contributing to the formation ofneurofila-
mentous axonal swellings, a lesion charac-
teristic of CS2 neurotoxicity. It was also
shown that cross-linking of neurofilament
proteins was positively correlated to CS2-
mediated covalent cross-linking of spec-
trin, a red blood cell membrane protein. A
linear dose-response relationship was
observed for these two biochemical events,
suggesting thatpopulations exposed to CS2
could be evaluated through periodic blood
sampling, and that the quantity ofspectrin
cross-linking could be used to identifypeo-
ple in danger ofdeveloping neurotoxicity.
Hemoglobin has a similar biological life to
that oferythrocyte spectrin, and is easier to
isolate and analyze. As part ofthe NIEHS
research, scientists sought to evaluate mod-
ified hemoglobin as a potential dosimeter
forquantifying exposure to CS2.
The study found that hemoglobin
modification does, indeed, possess several
advantages over spectrin cross-linking as a
biomarker of effect for CS2 exposure.
Modification ofhemoglobin can be detect-
ed at earlier time points than spectrin
dimer formation. Analysis ofhemoglobin
requires drawing far less blood than that of
spectrin and can be performed with more
direct and rapid methods. Collectively, the
findings suggest that alterations in the
alpha chain ofhemoglobin may provide a
sensitive neurotoxic biomarker ofeffect for
CS2 with the potential to provide mecha-
nistically relevant assessments ofsubchron-
ic exposures, a tool to help identifysuscep-
tible individuals, and a means to examine
possible effects occurring at presently
acceptable levels ofCS2 exposure.
Researchers also examined the potential
of using mRNA expression of NGF-R as
an early indicator of peripheral nervous
system damage. One of the effects of
chronic CS2 exposure is the retraction of
myelin, the fatty substance that ensheathes
nerve fibers. Previous research had shown
that mRNA levels are markedly upregulat-
ed in the sciatic nerve during demyelina-
tion. Upregulation also occurs in various
subdegenerative axonopathy models where
there is axonal atrophy. These findings
suggested that mRNA upregulation could
be a useful biomarker for subtle perturba-
tions in normal axon-Schwann cell inter-
actions. To further test this hypothesis, the
team examined NGF-R mRNA expression
in sciatic nerves ofrats exposed to CS2.
The study revealed that NGF-R
mRNA expression does increase in a dose-
and time-dependent manner. Morphologic
alterations in the sciatic nerve were not
apparent, even at the highest dosages with
the longest exposure times. Thus, upregu-
lation ofNGF-R mRNA is an indicator of
subtle alterations in the normal
axon-Schwann cell relationship and does
provide a sensitive measure of CS2 neuro-
toxicity. Researchers state that the assay of
this marker may also be useful as a rapid
and sensitive general screen for other com-
pounds that are potentially toxic to the
peripheral nervous system.
One ofthe most widely reported find-
ings in people and animals exposed to CS2
is neurotoxicity in the central and periph-
eral nervous system. Yet few studies have
fully examined the morphologic progres-
sion, biology, and mechanism of CS2-
induced neurotoxicity. Therefore, the
researchers conducted a study to examine
the progression and dose response of CS2
distal axonopathy by light and electron
microscopy and in teased nerve fiber
preparations. They then correlated these
observations with otherbiologicand mech-
anisticfindings using inhalation studies.
The study revealed that both behav-
ioral changes and biochemical effects, such
as cross-linking ofhemoglobin and neuro-
filament proteins, and increases in NGF-R
mRNA expression occur prior to axonal
swelling. The study illustrates that the
detection of neurotoxic effects prior to
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morphologic changes can be used to dis-
cern potential neurotoxicity and mecha-
nisms oftoxicity.
A frequently cited functional change
following CS2 exposure is a decrease in
NCV. The researchers hypothesized that
alterations in peripheral nerve function pro-
duced by CS2 exposure would be reflected
in changes in CNAP and/or NCV. Using
electrophysiological testing and microscop-
ic examination of the ventral caudal tail
nerve, researchers quantified concentration-
and time-related changes in peripheral
nerve electrophysiology produced by sub-
chronic exposure to CS2. This study
revealed that exposures to 500 ppm or 800
ppm CS2 for 8-13 weeks produced some
minor changes in NCV and CNAP record-
ed from the ventral caudal tail nerves of
experimental animals. The biological basis
for the changes in CNAP produced by CS2
is currentlyunder investigation.
A final study measured behavioral
changes in test animals using a FOB.
Neuromuscular deficits, including gait
alterations and decreased hindlimb and
forelimb grip strength, were detected in
the test animals after as little as two weeks'
exposure to 800 ppm CS2. These changes
were closely related to CS2 concentration
and exposure duration. Other effects,
observed mostly at 13 weeks, included
decreased responsiveness to a visual stimu-
lus and mild tremors. Correlations with
other endpoints in the project demonstrate
that behavioral changes can be a sensitive
indicator ofCS2 neurotoxicity.
Further Research
The carbon disulfide studies carried out at
the NIEHS, which were published in a series
ofeight papers in the February 1998 issue of
Neurotoxicology, have spurred further
research in this area. Valentine and Graham,
both now at Vanderbilt University Medical
Center in Nashville, Tennessee, used sam-
ples from the NIEHS studies in astudy pub-
lished in the January 1997 issue of
Toxicology andApplied Pharmacology that
demonstrated the sensitivity of spectrin
cross-linking for detecting inhalation expo-
sures to CS2, and provided evidence for
covalent cross-linking ofneurofilament pro-
teins as a mechanism for CS2-induced axon-
al neurofilamentous swellings. They also
used the biomarkers developed in the CS2
inhalation study in a second study, pub-
lished in the February 1998 issue of the
samejournal, to quantify the amount ofCS2
liberated by diethyldithiocarbamate in vivo.
Athirdstudy, published in the May 1998 issue
of ChemicalResearch in Toxicology, established
the formation ofCS2-mediated thiourea pro-
teincross-linksonspectrn in vivo.
Valentine and Graham now intend to
investigate the utility ofCS2-mediated pro-
tein modifications for monitoring high-risk
human populations. "The information
derived from the human studies should
indicate how useful our biomarkers are for
developing intervention strategies for iden-
tifying and removing individuals from
neurotoxic levels of CS2 or compounds
that release CS2 prior to their developing
neurological deficits," says Valentine.
The EPA, meanwhile, anticipates using
the data from the CS2 studies for a series of
actions defined under the Clean Air Act
Amendments of 1990. "These studies will
be vital to the EPA for development and
refinement of mechanistically based quan-
titative human health risk assessments for
chemicals listed in the Clean Air Act," says
Gary Foureman, a health scientist with the
EPA's National Center for Environmental
Assessment in Research Triangle Park.
"These risk assessments, in turn, are used
for such measures as the listing and delist-
ing of hazardous air pollutants, setting of
emission standards through Maximum
Achievable Control Technology, and pro-
viding technical assistance through air toxi-
cs clearinghouses such as the Air Risk
Information Support Center."
John Manuel
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